M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

Pharmaceutical Business Review

The initiative aligns with China's and the United Arab Emirates' (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Business Review

The initiative aligns with China’s and the United Arab Emirates’ (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

Related Stories

Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact

Rocket to sell PRV for $180m to advance gene therapy pipeline

AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

You May Have Missed

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

AZ, Amgen will pilot FDA’s real-time clinical trial plan

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’